Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.60 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.57 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.50 |
| ▸ | GABRE | P78334 | 2/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11188341 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| SCHEMBL7937311 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| SCHEMBL29959406 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| SCHEMBL7762097 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| SCHEMBL1270356 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| SCHEMBL23044064 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| Hydrochloric Acid SCHEMBL8728073 | 0.98 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| Hydrochloric Acid SCHEMBL11283847 | 0.98 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| Hydrochloric Acid SCHEMBL8728071 | 0.98 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLANOD1GABRP | |
| SCHEMBL28727840 | 0.96 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLANOD1GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504166-B1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 THERAPEUTICS LTD (GB) | 2026-04-29 | — | — | EP | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260034090-A1 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2026-02-05 | — | — | US | claimed |
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20250222063-A1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF DRY ITCHY SKIN | MC2 THERAPEUTICS LTD (GB) | 2025-07-10 | — | — | US | claimed |
| CN-120084911-A | Method for measuring alanyl glutamine related substances | 苏州科伦药物研究有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-113933403-B | Method for measuring alanyl glutamine related substances | 苏州科伦药物研究有限公司 | 2025-04-25 | — | — | CN | claimed |
| EP-4504166-A1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN | MC2 Therapeutics Limited (GB) | 2025-02-12 | — | — | EP | claimed |
| CN-119224161-A | Method for detecting various dipeptides in rumen fluid of ruminant | 中国科学院亚热带农业生态研究所 | 2024-12-31 | — | — | CN | claimed |
| CN-111296222-A | Transplanting process for big trees | 华绿建设有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-108514529-A | A kind of extracting method and application thereof of skin-lightening cosmetic Chinese medical extract | 张言聚 | 2018-09-11 | — | — | CN | claimed |
| WO-2018065279-A1 | METHOD OF REDUCING MALODOUR | UNILEVER PLC (GB) | 2018-04-12 | — | — | WO | claimed |
| US-8815800-B2 | Moisturizing composition comprising an aminopeptide mixture | CONOPCO, INC. (US) | 2014-08-26 | — | — | US | claimed |
| CN-1602190-A | Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis | ESSENTYS AB (SE) | 2005-03-30 | — | — | CN | claimed |
| US-20040259766-A1 | Bone disorders; administering to mammals, humans, poultry | PROTISTA CORPORATION AB (SE) | 2004-12-23 | — | — | US | claimed |
| EP-1446112-A1 | USE OF GLUTAMATE, GLUTAMATE DERIVATIVES OR METABOLITES, GLUTAMATE ANALOGUES OR MIXTURES THEREOF FOR THE MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS | Essentys AB (SE) | 2004-08-18 | — | — | EP | claimed |
| WO-2003043626-A1 | USE OF GLUTAMATE, GLUTAMATE DERIVATIVES OR METABOLITES, GLUTAMATE ANALOGUES OR MIXTURES THEREOF FOR THE MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS | ESSENTYS AB (SE) | 2003-05-30 | — | — | WO | claimed |
| US-6063613-A | MUTANT STAPHYLOCOCCUS AUREUS CAUSED BY INSERTION OF TRANSPOSON TN551; CAUSES INCORPORATION OF PARTIALLY BLOCKED MUROPEPTIDE PRECURSORS INTO CELL WALL; FOR SCREENING DRUGS THAT CAN REVERSE, INHIBIT OR REDUCE BACTERIAL RESISTANCE | THE ROCKEFELLER UNIVERSITY (US) | 2000-05-16 | — | — | US | claimed |
| WO-1995016039-A1 | AUXILIARY GENES AND PROTEINS OF METHICILLIN RESISTANT BACTERIA AND ANTAGONISTS THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 1995-06-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222063-A1 | TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF DRY ITCHY SKIN | SLC14A1, ITCH, HNMT | FOLH1 1060/4885NAALAD2 204/4885RIMKLA 1980/4885 |
| US-20260034090-A1 | CANNABINOID PRODRUG COMPOUNDS | CNR1, CNR2, FAAH | FOLH1 941/4885NAALAD2 2634/4885RIMKLA 567/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | FOLH1 387/4885NAALAD2 4066/4885RIMKLA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.